CONSUN PHARMA: CLARIFICATION ANNOUNCEMENT
Changes in Hong Kong stocks | Kangchen Pharmaceutical (01681) rose more than 6% and plans to review the special dividend issuance next Friday. The company's profit double increased last year
Kangchen Pharmaceutical (01681) rose more than 6%. As of press release, it rose 6.43% to HK$6.95, with a turnover of HK$10.996 million.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Kangchen Pharmaceutical (01681.HK) plans to hold a board meeting on May 24 to review and approve the special dividend announcement
Glonghui, May 13, 丨 Kangchen Pharmaceutical (01681.HK) announced that the company will hold a board meeting on May 24, 2024 (Friday) to review and approve the issuance of special dividends and handle any other business (if any): if approved by the board of directors, the company will publish the company separately after the board meeting to include details of the special dividend.
CONSUN PHARMA: Notice of Board Meeting
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program
Consun Pharmaceutical Group (HKG:1681) plans to grant share options of about 8.2 million shares, representing 10% of the company's total issued shares, according to a Tuesday filing on the Hong Kong b
康臣葯業:股東周年大會通告
康臣葯業:2023 年度報告
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Kangchen Pharmaceutical (1681.HK): Significant advantages in the field of nephrology, performance continues to grow rapidly
Key investment results continued to grow rapidly: Since the company went public in 2013, as of 2023, operating income CAGR was 16.3%, and net profit CAGR was 17.8%. The growth rate in the industry has clearly slowed or even declined
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Keep integrity, innovate, and go farway丨Understand Kangchen Pharmaceutical (1681.HK)'s 2023 performance in one picture
Recently, Kangchen Pharmaceutical (1681.HK), the market leader in proprietary Chinese medicines for nephropathy, announced the results for the year ended December 31, 2023. The following will show you the 2023 annual results of Kangson Pharmaceuticals through a chart.
CONSUN PHARMA To Go Ex-Dividend On June 11th, 2024 With 0.3 HKD Dividend Per Share
March 30th - $CONSUN PHARMA(01681.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.3 HKD dividend per share on June 21st, 2024. The ex-divid
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit
Consun Pharmaceutical Group (HKG:1681) posted a 2023 profit attributable to shareholders of 784.5 million yuan, or 0.98 yuan per share, up from 682.9 million yuan, or 0.86 yuan per share, a year earli
No Data